InflaRx initiated at Credit Suisse

InflaRx initiated with an Outperform at Credit Suisse. Credit Suisse analyst Tiago Fauth started coverage of InflaRx with an Outperform rating and $47 price target. The analyst believes the stock will outperform based on a favorable risk/reward into a potentially meaningfully de-risking Phase 2b clinical update for IFX-1 in HS and increasing investor recognition of the substantial and growing opportunity in the HS market.
https://thefly.com/landingPageNews.php?id=2834523